Chlamydia psittaci (C. psittaci)

Chlamydia psittaci is an obligate intracellular Gram-negative bacterium and the causative agent of psittacosis, a zoonotic disease transmitted to humans primarily from birds. As a pathogen, it is not a singular molecular target but rather an organism containing multiple therapeutic targets, such as the 30S ribosomal subunit and various metabolic enzymes essential for its unique biphasic life cycle involving elementary bodies and reticulate bodies. Human infection typically occurs via inhalation of aerosolized droppings or respiratory secretions from infected avian species, leading to systemic infection characterized by fever, headache, and atypical pneumonia. Therapeutic intervention requires the use of lipophilic antibiotics, such as tetracyclines or macrolides, which can penetrate host cell membranes to reach the pathogen within its intracellular inclusion. While Chlamydia psittaci remains sensitive to standard anti-chlamydial regimens, its intracellular nature and the potential for severe multi-organ complications necessitate prompt diagnosis and targeted antimicrobial therapy.

Other names

Chlamydophila psittaciPsittacosis agentOrnithosis agentBedsonia

Antibiotics used against Chlamydia psittaci primarily act by inhibiting bacterial protein synthesis through binding to the 30S or 50S ribosomal subunits, or by inhibiting DNA replication through the targeting of DNA gyrase and topoisomerase IV.